###begin article-title 0
###xml 41 46 41 46 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 47 49 47 49 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
A Candidate Gene Approach Identifies the TRAF1/C5 Region as a Risk Factor for Rheumatoid Arthritis
###end article-title 0
###begin title 1
Background
###end title 1
###begin p 2
###xml 498 525 474 501 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">complement component 5 (C5)</italic>
###xml 533 574 509 550 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF receptor-associated factor 1 (TRAF1),</italic>
###xml 231 236 <span type="species:ncbi:9606">human</span>
###xml 446 450 <span type="species:ncbi:10090">mice</span>
Rheumatoid arthritis (RA) is a chronic autoimmune disorder affecting approximately1% of the population. The disease results from the interplay between an individual's genetic background and unknown environmental triggers. Although human leukocyte antigens (HLAs) account for approximately30% of the heritable risk, the identities of non-HLA genes explaining the remainder of the genetic component are largely unknown. Based on functional data in mice, we hypothesized that the immune-related genes complement component 5 (C5) and/or TNF receptor-associated factor 1 (TRAF1), located on Chromosome 9q33-34, would represent relevant candidate genes for RA. We therefore aimed to investigate whether this locus would play a role in RA.
###end p 2
###begin title 3
Methods and Findings
###end title 3
###begin p 4
###xml 103 108 103 108 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 113 126 113 126 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5 (TRAF1/C5)</italic>
###xml 332 333 332 333 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 333 347 333 347 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cases/controls</sub>
###xml 368 369 368 369 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 369 383 369 383 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cases/controls</sub>
###xml 407 408 407 408 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 408 422 408 422 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cases/controls</sub>
###xml 474 475 474 475 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 577 579 577 579 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 591 596 591 596 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 714 716 702 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 721 726 709 714 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 844 850 832 838 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">common</sub>
###xml 894 895 882 883 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 895 903 883 891 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">combined</sub>
###xml 915 917 903 905 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 1140 1141 1128 1129 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 153 161 <span type="species:ncbi:9606">patients</span>
###xml 181 193 <span type="species:ncbi:9606">participants</span>
###xml 805 813 <span type="species:ncbi:9606">patients</span>
###xml 1130 1138 <span type="species:ncbi:9606">patients</span>
We performed a multitiered case-control study using 40 single-nucleotide polymorphisms (SNPs) from the TRAF1 and C5 (TRAF1/C5) region in a set of 290 RA patients and 254 unaffected participants (controls) of Dutch origin. Stepwise replication of significant SNPs was performed in three independent sample sets from the Netherlands (ncases/controls = 454/270), Sweden (ncases/controls = 1,500/1,000) and US (ncases/controls = 475/475). We observed a significant association (p < 0.05) of SNPs located in a haplotype block that encompasses a 65 kb region including the 3' end of C5 as well as TRAF1. A sliding window analysis revealed an association peak at an intergenic region located approximately10 kb from both C5 and TRAF1. This peak, defined by SNP14/rs10818488, was confirmed in a total of 2,719 RA patients and 1,999 controls (odds ratiocommon = 1.28, 95% confidence interval 1.17-1.39, pcombined = 1.40 x 10-8) with a population-attributable risk of 6.1%. The A (minor susceptibility) allele of this SNP also significantly correlates with increased disease progression as determined by radiographic damage over time in RA patients (p = 0.008).
###end p 4
###begin title 5
Conclusions
###end title 5
###begin p 6
###xml 136 144 136 144 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1/C5</italic>
###xml 281 286 281 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 294 296 294 296 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
Using a candidate-gene approach we have identified a novel genetic risk factor for RA. Our findings indicate that a polymorphism in the TRAF1/C5 region increases the susceptibility to and severity of RA, possibly by influencing the structure, function, and/or expression levels of TRAF1 and/or C5.
###end p 6
###begin p 7
###xml 128 136 128 136 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1/C5</italic>
Using a candidate-gene approach, Rene Toes and colleagues identified a novel genetic risk factor for rheumatoid arthritis in theTRAF1/C5 region.
###end p 7
###begin title 8
Editors' Summary
###end title 8
###begin title 9
Background.
###end title 9
###begin p 10
###xml 80 86 <span type="species:ncbi:9606">people</span>
###xml 569 577 <span type="species:ncbi:9606">patients</span>
###xml 827 832 <span type="species:ncbi:9606">human</span>
Rheumatoid arthritis is a very common chronic illness that affects around 1% of people in developed countries. It is caused by an abnormal immune reaction to various tissues within the body; as well as affecting joints and causing an inflammatory arthritis, it can also affect many other organs of the body. Severe rheumatoid arthritis can be life-threatening, but even mild forms of the disease cause substantial illness and disability. Current treatments aim to give symptomatic relief with the use of simple analgesics, or anti-inflammatory drugs. In addition, most patients are also treated with what are known as disease-modifying agents, which aim to prevent joint damage. Rheumatoid arthritis is known to have a genetic component. For example, an association has been shown with the part of the genome that contains the human leukocyte antigens (HLAs), which are involved in the immune response. Information on other genes involved would be helpful both for understanding the underlying cause of the disease and possibly for the discovery of new treatments.
###end p 10
###begin title 11
Why Was This Study Done?
###end title 11
###begin p 12
###xml 153 180 153 180 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">complement component 5 (C5)</italic>
###xml 426 466 426 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF receptor-associated factor 1 (TRAF1)</italic>
###xml 17 21 <span type="species:ncbi:10090">mice</span>
###xml 53 58 <span type="species:ncbi:9606">human</span>
###xml 315 321 <span type="species:ncbi:9606">humans</span>
###xml 491 497 <span type="species:ncbi:9606">humans</span>
Previous work in mice that have a disease similar to human rheumatoid arthritis has identified a number of possible candidate genes. One of these genes, complement component 5 (C5) is involved in the complement system-a primitive system within the body that is involved in the defense against foreign molecules. In humans the gene for C5 is located on Chromosome 9 close to another gene involved in the inflammatory response, TNF receptor-associated factor 1 (TRAF1). A preliminary study in humans of this region had shown some evidence, albeit weak, to suggest that this region might be associated with rheumatoid arthritis. The authors set out to look in more detail, and in a larger group of individuals, to see if they could prove this association.
###end p 12
###begin title 13
What Did the Researchers Do and Find?
###end title 13
###begin p 14
###xml 131 133 131 133 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 138 143 138 143 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 729 731 729 731 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 752 757 752 757 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 236 241 <span type="species:ncbi:9606">human</span>
###xml 378 386 <span type="species:ncbi:9606">patients</span>
###xml 432 444 <span type="species:ncbi:9606">participants</span>
###xml 516 524 <span type="species:ncbi:9606">patients</span>
The researchers took 40 genetic markers, known as single-nucleotide polymorphisms (SNPs), from across the region that included the C5 and TRAF1 genes. SNPs have each been assigned a unique reference number that specifies a point in the human genome, and each is present in alternate forms so can be differentiated. They compared which of the alternate forms were present in 290 patients with rheumatoid arthritis and 254 unaffected participants of Dutch origin. They then repeated the study in three other groups of patients and controls of Dutch, Swedish, and US origin. They found a consistent association with rheumatoid arthritis of one region of 65 kilobases (a small distance in genetic terms) that included one end of the C5 gene as well as the TRAF1 gene. They could refine the area of interest to a piece marked by one particular SNP that lay between the genes. They went on to show that the genetic region in which these genes are located may be involved in the binding of a protein that modifies the transcription of genes, thus providing a possible explanation for the association. Furthermore, they showed that one of the alternate versions of the marker in this region was associated with more aggressive disease.
###end p 14
###begin title 15
What Do These Findings Mean?
###end title 15
###begin p 16
The finding of a genetic association is the first step in identifying a genetic component of a disease. The strength of this study is that a novel genetic susceptibility factor for RA has been identified and that the overall result is consistent in four different populations as well as being associated with disease severity. Further work will need to be done to confirm the association in other populations and then to identify the precise genetic change involved. Hopefully this work will lead to new avenues of investigation for therapy.
###end p 16
###begin title 17
Additional Information.
###end title 17
###begin p 18
Please access these Web sites via the online version of this summary at .
###end p 18
###begin p 19
###xml 36 44 <span type="species:ncbi:9606">patients</span>
* , the health information site for patients from the US National Library of Medicine, has a page of resources on rheumatoid arthritis
###end p 19
###begin p 20
* The UK's  online information site has information on rheumatoid arthritis
###end p 20
###begin p 21
###xml 103 111 <span type="species:ncbi:9606">patients</span>
* The , a UK charity that funds research on all types of arthritis, has a booklet with information for patients on rheumatoid arthritis
###end p 21
###begin p 22
* , a Dutch arthritis foundation, gives information on rheumatoid arthritis (in Dutch)
###end p 22
###begin p 23
###xml 135 143 <span type="species:ncbi:9606">patients</span>
*  is an initiative whose objective is to transform knowledge obtained from molecular research into a cure for an increasing number of patients suffering from inflammatory rheumatic diseases
###end p 23
###begin p 24
###xml 41 48 <span type="species:ncbi:9606">patient</span>
* , an organisation which represents the patient, health professionals, and scientific societies of rheumatology of all European nations
###end p 24
###begin title 25
Introduction
###end title 25
###begin p 26
###xml 448 449 448 449 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b001">1</xref>
###xml 528 529 528 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b002">2</xref>
###xml 530 531 530 531 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b003">3</xref>
Rheumatoid arthritis (RA) is characterized by chronic inflammation and destruction of the synovial joints leading to progressive joint damage and disability. The disease has a complex etiology, including a wide spectrum of clinical manifestations, variability in disease severity and/or progression, and differential response to a range of therapies. This heterogeneous phenotype suggests the involvement of both environmental and genetic factors [1], where the genetic component of RA has been estimated to be between 50%-60% [2,3]. Identification of disease-associated genes is important as it will guide our understanding of the biological pathways underlying polygenic diseases and the development of potential novel therapeutic targets.
###end p 26
###begin p 27
###xml 64 93 64 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">human leukocyte antigen (HLA)</italic>
###xml 270 271 270 271 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b002">2</xref>
###xml 272 273 272 273 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b004">4</xref>
###xml 333 336 333 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 400 470 400 470 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">protein tyrosine phosphatase, non-receptor type 22 (lymphoid) (PTPN22)</italic>
###xml 578 579 578 579 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b005">5</xref>
###xml 610 616 610 616 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PTPN22</italic>
###xml 630 633 630 633 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">HLA</italic>
###xml 920 921 912 913 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b006">6</xref>
###xml 1262 1289 1254 1281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">complement component 5 (C5)</italic>
###xml 1401 1402 1393 1394 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b007">7</xref>
###xml 1403 1404 1395 1396 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b008">8</xref>
###xml 1456 1457 1448 1449 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">,</italic>
###xml 1555 1567 1547 1559 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5a receptor</italic>
###xml 1684 1685 1676 1677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b009">9</xref>
###xml 1686 1688 1678 1680 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b010">10</xref>
###xml 1853 1855 1845 1847 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 1864 1866 1856 1858 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b011">11</xref>
###xml 64 69 <span type="species:ncbi:9606">human</span>
###xml 1157 1161 <span type="species:ncbi:10090">mice</span>
###xml 1373 1378 <span type="species:ncbi:10090">mouse</span>
###xml 1518 1526 <span type="species:ncbi:9606">patients</span>
###xml 1578 1582 <span type="species:ncbi:10090">mice</span>
###xml 1708 1712 <span type="species:ncbi:10090">mice</span>
The most prominent genetic association in RA is confined to the human leukocyte antigen (HLA) locus. Although this association has been known for almost 30 years, and although the underlying mechanism is still not understood, it has been replicated in multiple studies [2,4]. The identification of RA-associated genes outside of the HLA region, however, has been a challenge. Recently one such gene, protein tyrosine phosphatase, non-receptor type 22 (lymphoid) (PTPN22), was identified in the first step of a large genetic-association study utilizing putative functional SNPs [5]. The gene product encoded by PTPN22 is, like the HLA locus, involved in T cell-mediated immune responses. However, other immune components are also thought to play a pivotal role in RA, as demonstrated by the beneficial effects of treatment with agents that block proinflammatory cytokines, such as tumor necrosis factor alpha (TNFalpha) [6]. Moreover, in several experimental animal models for RA, innate immune responses mediated by a diversity of players have been implicated in arthritis. In this respect, a prominent role for the complement system has been identified as mice deficient in complement factors are resistant to arthritis, and as it has been shown that targeting complement component 5 (C5) by antibodies prevents the onset of arthritis and reduces the clinical severity in mouse models for arthritis [7,8]. Likewise, the observation that high levels of C5a, a potent chemoattractant, are found in synovial fluid of RA patients combined with the fact that C5a receptor-deficient mice are also resistant to arthritis induction, indicate a central role for these mediators in arthritis [9,10]. A genome scan of mice that were or were not susceptible to antibody-induced arthritis revealed that the main genetic influence detected in this model maps to the C5 region [11].
###end p 27
###begin p 28
###xml 66 68 66 68 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 392 394 392 394 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 403 405 403 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b012">12</xref>
###xml 551 553 551 553 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 573 613 573 613 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TNF receptor-associated factor 1 (TRAF1)</italic>
###xml 853 855 853 855 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 860 866 860 866 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1,</italic>
###xml 25 29 <span type="species:ncbi:10090">mice</span>
###xml 729 733 <span type="species:ncbi:10090">mice</span>
###xml 738 744 <span type="species:ncbi:9606">humans</span>
These functional data in mice inspired us to hypothesize that the C5 region would be a contributing factor in RA. Therefore, we searched for further evidence by first addressing the question of whether any genetic indications exist that implicate the involvement of this region in RA. A conventional linkage study using microsatellite markers identified a linkage peak in the vicinity of the C5 region [12]. Although this study provided weak evidence for linkage (logarithm of the odds score, LOD 1.8), it further boosted our interest in this region. C5 is located next to TNF receptor-associated factor 1 (TRAF1), an essential effector of the TNF signaling cascade. Since TNF blockade represents a powerful intervention in both mice and humans for the treatment of arthritis, it provided an additional rationale to explore this genetic region encoding C5 and TRAF1, which are adjacent to each other on Chromosome 9q33-34. We therefore sought to investigate whether these candidate genes, which are important immune mediators, would play a role in RA.
###end p 28
###begin title 29
Methods
###end title 29
###begin title 30
Study Populations
###end title 30
###begin p 31
###xml 113 115 113 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b013">13</xref>
###xml 7 15 <span type="species:ncbi:9606">patients</span>
All RA patients in all sets in this study met the American College of Rheumatology 1987 revised criteria for RA [13].
###end p 31
###begin p 32
###xml 142 144 142 144 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b014">14</xref>
###xml 39 47 <span type="species:ncbi:9606">patients</span>
###xml 84 91 <span type="species:ncbi:9606">patient</span>
Sample set 1 cases consisted of 290 RA patients consecutively included from the out-patient clinic of the Leiden University Hospital in 1994 [14] and 254 controls randomly selected by the section Immunogenetics and Transplantation Immunology of Leiden University Medical Center, Leiden, The Netherlands (ITI).
###end p 32
###begin p 33
###xml 1245 1247 1237 1239 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b015">15</xref>
###xml 1248 1250 1240 1242 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b016">16</xref>
###xml 33 41 <span type="species:ncbi:9606">patients</span>
###xml 157 165 <span type="species:ncbi:9606">patients</span>
###xml 212 220 <span type="species:ncbi:9606">patients</span>
###xml 336 344 <span type="species:ncbi:9606">patients</span>
###xml 530 538 <span type="species:ncbi:9606">patients</span>
###xml 578 586 <span type="species:ncbi:9606">Patients</span>
###xml 646 654 <span type="species:ncbi:9606">Patients</span>
###xml 779 787 <span type="species:ncbi:9606">Patients</span>
###xml 1113 1121 <span type="species:ncbi:9606">patients</span>
Since 89% of the first set of RA patients were rheumatoid factor (RF) positive, we genotyped an independent sample set 2, which consisted of 454 RF-positive patients from two inception cohorts of early arthritis patients (EAC and BEST) and a second set of 270 randomly selected Dutch blood donors from ITI. Briefly, the EAC consists of patients included from 1993 onwards and originating from a health care region of about 400,000 inhabitants in the western part of The Netherlands. General practitioners were encouraged to refer patients directly when arthritis was suspected. Patients were included when the symptom duration was less than 2 y. Patients from the BEST study were recruited between March 2000 and August 2002 at 20 centers in the western part of The Netherlands. Patients had a maximum disease duration of 2 y, were at least 18 y of age, and had active disease (defined as >/= six swollen joints, >/= six tender joints, and either an erythrocyte sedimentation rate of >/= 28 mm/h or a global health assessment score of >/= 20 on a 100-mm visual analog scale, where 0 = best and 100 = worst). Only patients with a diagnosis of RA were included in the present study. These cohorts are further described in detail in other reports [15,16].
###end p 33
###begin p 34
###xml 160 162 160 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b017">17</xref>
###xml 35 43 <span type="species:ncbi:9606">patients</span>
###xml 83 95 <span type="species:ncbi:9606">participants</span>
###xml 177 185 <span type="species:ncbi:9606">patients</span>
###xml 332 344 <span type="species:ncbi:9606">participants</span>
Sample set 3 consisted of 1,500 RA patients (70% RF-positive) and 1,000 unaffected participants (controls) from the Swedish EIRA study as previously described [17]. Briefly, RA patients and controls aged 18-70 y during May 1996 to December 2003 from a geographically defined area in the south and central regions of Sweden. Control participants were randomly selected from a continuously updated national population register, with consideration given to age, sex, and living area. If the selected control was not traceable, reported having RA, or refused to participate, a new control was selected using the same procedure.
###end p 34
###begin p 35
###xml 195 196 195 196 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b005">5</xref>
###xml 92 100 <span type="species:ncbi:9606">patients</span>
Sample set 4, obtained from the Genomics Collaborative, (GCI), comprised 475 RF-positive RA patients and 475 individually matched controls from the US and has been described in detail elsewhere [5]. In brief, all case samples were from white North Americans who were RF-positive and whose condition met the 1987 American College of Rheumatology diagnostic criteria for RA. Control samples were taken from a pool of healthy white individuals with no medical history of RA. A single control was matched to each case on the basis of sex, age (+/-5 y), and ethnicity (grandparental country/region of origin).
###end p 35
###begin p 36
###xml 197 205 193 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040278-st001">Table S1</xref>
###xml 0 8 <span type="species:ncbi:9606">Patients</span>
###xml 155 163 <span type="species:ncbi:9606">patients</span>
###xml 313 321 <span type="species:ncbi:9606">patients</span>
###xml 541 553 <span type="species:ncbi:9606">participants</span>
Patients from sample sets 1 and 4 had considerably longer disease duration at inclusion (13.8 +/- 10.1 y and 11.7 +/- 10.0 y, respectively) as compared to patients from sample sets 2 and 3 (<3 y) (Table S1). All controls were healthy unrelated white individuals originating from the same geographical area as the patients. There was no overlap between cases and controls across all studies. All protocols and recruitments were approved by national and/or local institutional review boards, and informed written consent was obtained from all participants.
###end p 36
###begin title 37
SNP Selection and Genotyping
###end title 37
###begin p 38
###xml 35 40 35 40 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 41 43 41 43 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 69 90 69 90 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHD finger protein 19</italic>
###xml 92 97 92 97 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHF19</italic>
###xml 103 130 103 130 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">centrosomal protein 110 kDa</italic>
###xml 132 139 132 139 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CEP110)</italic>
###xml 156 163 156 163 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040278-t001">Table 1</xref>
###xml 642 653 642 653 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040278-sd001">Protocol S1</xref>
We chose 40 polymorphisms spanning TRAF1/C5 and their flanking genes PHD finger protein 19 (PHF19) and centrosomal protein 110 kDa (CEP110) for this study (Table 1). We selected haplotype tagging SNPs (htSNPs) from the International HapMap Project database () as well as random SNPs from the University of California Santa Cruz database () to ascertain maximum haplotype information for each of the genes and intergenic regions that are likely to harbor regulatory regions. Chromosomal locations of the SNPs were extracted from SNPPER () Goldenpath hg17, dbSNP build 123. Genotyping across all studies was performed as described in detail in Protocol S1. Three of the 40 SNPs were excluded from further analysis after reviewing results from sample set 1, two of which (SNP13/rs4837803 and SNP27/rs10119768) were not polymorphic and one (SNP35/rs7856420) of which deviated from Hardy-Weinberg equilibrium.
###end p 38
###begin p 39
Association of Candidate Gene SNPs with RA
###end p 39
###begin title 40
Statistical Analysis
###end title 40
###begin title 41
Single SNP and haplotype analysis.
###end title 41
###begin p 42
###xml 430 432 430 432 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b018">18</xref>
###xml 674 675 674 675 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 710 711 710 711 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 891 893 891 893 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b019">19</xref>
###xml 1076 1077 1076 1077 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1077 1078 1077 1078 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1078 1079 1078 1079 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 1088 1090 1088 1090 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b020">20</xref>
###xml 1097 1098 1097 1098 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1098 1099 1098 1099 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1099 1100 1099 1100 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 1317 1318 1317 1318 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 1318 1319 1318 1319 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1319 1320 1319 1320 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
Single SNP analysis and genetic model assessment was initially performed using SPSS version 12.0 (SPSS, ) in sample set 1. We did not find evidence of a recessive model for any SNPs. Since all SNPs were in Hardy-Weinberg equilibrium and adhered to the additive model of association, we performed further tests using allelic comparisons. Single- and multilocus allelic analyses were performed using Haploview version 3.32 (MIT, ) [18] with 40 SNPs in sample set 1 followed by six significant SNPs in sample set 2, the three most significant SNPs in sample set 3, and the single best-associating SNP in sample set 4. Odds ratios were calculated using Epi Info v6 (CDC, ). All p-values reported were two-sided. A p-value < 0.05 was considered significant. Based on the linkage disequilibrium (LD) structure in sample set 1, haplotype blocks were inferred under the algorithm of Gabriel et al. [19] in Haploview 3.32. To further minimize haplotypic uncertainty, we used the software TagSNPs version 1.0 () to identify eight htSNPs from block 2 and ten htSNPs from block 3 (global R2h > 98%) [20]. The R2h coefficient is the squared correlation between the true haplotype count (number of copies of a haplotype) and the haplotype count predicted by TagSNPs. We chose htSNPs so that haplotypes were predicted with a global R2h value of 0.95 or above, indicating a high accuracy. Haplotype analyses using these htSNPs were performed in Haploview 3.32.
###end p 42
###begin p 43
###xml 7 8 7 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 179 181 179 181 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b021">21</xref>
Global p-values for haplotype associations were calculated using the software Haplo.Stats version 1.2 () used for estimating haplotype effects under the generalized linear model [21]. htSNPs from blocks 2 and 3 in sample set 1 were further investigated by sliding-window analysis in Haploview 3.32 to determine the basis of the associated haplotypes.
###end p 43
###begin title 44
Combining datasets.
###end title 44
###begin p 45
###xml 135 137 135 137 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b022">22</xref>
###xml 263 265 263 265 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b023">23</xref>
###xml 327 328 327 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 337 345 337 345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040278-st002">Table S2</xref>
Odds ratios (OR)s from all sample sets were combined by the random model of the Cochran-Mantel-Haenszel test as implemented in EasyMA [22]. A Breslow-Day test of between-stage heterogeneity was also performed in EasyMA to test for consistency across sample sets [23]. We observed evidence of heterogeneity for SNP rs4836834 at p < 0.05 (Table S2).
###end p 45
###begin title 46
Logistics regression.
###end title 46
###begin p 47
###xml 285 293 285 293 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040278-st003">Table S3</xref>
Forward conditional logistics regression was performed using all six significant SNPs from sets 1 and 2 in SPSS 12.0. Genotypes were coded as categorical variables 0, 1, and 2 with the nonassociated genotype as reference. No evidence of a recessive effect was observed, as detailed in Table S3.
###end p 47
###begin title 48
Population attributable risk.
###end title 48
###begin p 49
###xml 98 101 98 101 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(P)</italic>
###xml 153 157 153 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(R),</italic>
###xml 170 172 170 172 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b024">24</xref>
Population-attributable risk (PAR) was calculated using the population prevalence of the exposure (P) and the relative risk associated with the exposure (R), as follows [24]. 
###end p 49
###begin title 50
Autoantibodies
###end title 50
###begin p 51
###xml 97 101 <span type="species:ncbi:9319">Euro</span>
###xml 418 426 <span type="species:ncbi:9606">patients</span>
###xml 497 505 <span type="species:ncbi:9606">patients</span>
###xml 532 540 <span type="species:ncbi:9606">patients</span>
Baseline laboratory parameters included IgM-RF (ELISA) and IgG-ACPA (ELISA, Immunoscan RA Mark2, Euro-Diagnostica, ). The cut-off for antibody positivity was set according to the manufacturer's instructions. Since baseline ACPA status was not available for most samples from the BEST study, we restricted our analysis to the EAC and EIRA cohorts. Autoantibody (RF and ACPA) and genotype status were available from 419 patients from the EAC (we additionally genotyped RF-negative and ACPA-negative patients in this cohort) and 1,395 patients from the EIRA study.
###end p 51
###begin title 52
Severity
###end title 52
###begin p 53
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 166 168 166 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b025">25</xref>
###xml 335 336 335 336 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 435 436 435 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 225 230 <span type="species:ncbi:12440">non-A</span>
###xml 313 318 <span type="species:ncbi:12440">non-A</span>
###xml 413 418 <span type="species:ncbi:12440">non-A</span>
Radiographs of hands and feet were scored at baseline and 2 y (n = 278) using the Sharp-van der Heijde method (erosions and joint space narrowing of hands and feet) [25]. Data was available from 193 A carriers (AA+AG) and 85 non-A carriers (GG) from the EAC cohort. The prevalence of either RF (A carriers 60.9%, non-A carriers 56.5%, p = 0.485) or anti-citrullinated protein antibodies (ACPA) (A carriers 60.7%, non-A carriers 60.8%, p = 0.986) is not significantly different between the two groups analyzed. Differences in means between groups were calculated using sharp scores adjusted for baseline with a two-sided nonparametric Mann-Whitney test.
###end p 53
###begin title 54
Transcription Factor Binding Sites
###end title 54
###begin p 55
###xml 301 303 301 303 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b026">26</xref>
Transcription factor binding sites (TFBSs) were predicted using MAPPER (), a platform that combines information from two well-known TFBS databases, TRANSFAC and JASPAR. The prediction is generated from a hidden Markov model and is based on experimentally determined binding sites in multiple genomes [26].
###end p 55
###begin title 56
Results
###end title 56
###begin title 57
###xml 4 9 4 9 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 10 12 10 12 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
The TRAF1/C5 Region Associates with RA
###end title 57
###begin p 58
###xml 27 32 27 32 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 33 35 33 35 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
To investigate whether the TRAF1/C5 region on Chromosome 9q33-34 associates with RA, we selected a total of 40 polymorphisms spanning these candidates and their flanking genes for genotyping. Tagging SNPs as well as random SNPs were included to ascertain maximum haplotype information for each of the genes and to ensure coverage of intergenic regions which may harbor regulatory polymorphisms.
###end p 58
###begin p 59
###xml 63 64 63 64 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 86 87 86 87 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 152 157 152 157 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 158 160 158 160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 208 209 208 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 279 286 279 286 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040278-t001">Table 1</xref>
###xml 300 305 300 305 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHF19</italic>
###xml 335 341 335 341 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CEP110</italic>
###xml 403 404 403 404 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 53 61 <span type="species:ncbi:9606">patients</span>
Single SNP analysis performed in the first set of RA patients (n = 290) and controls (n = 254) revealed significant association between six SNPs in the TRAF1/C5 region (SNPs 4, 7, 10, 14, 15, and 16) and RA (p = 0.0104, 0.0153, 0.0080, 0.0039, 0.0039, and 0.0250, respectively) (Table 1). One SNP in PHF19 (SNP3/rs10985070) and one in CEP110 (SNP36/rs10818503) also showed moderate association with RA (p = 0.0387 and 0.0257, respectively). None of the SNPs investigated showed evidence of a recessive mode of association.
###end p 59
###begin p 60
###xml 378 384 378 384 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHF19;</italic>
###xml 406 411 406 411 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 463 466 463 466 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5;</italic>
###xml 520 522 520 522 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 532 538 532 538 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CEP110</italic>
###xml 540 548 540 548 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040278-g001">Figure 1</xref>
To delineate the haplotypic architecture, we estimated the underlying haplotype block structure of the 32 SNPs with minor allele frequency > 5% in the controls. We identified a potential recombination spot at SNP3/rs10985070 and SNP24/rs7026551 that divides the region into three inheritance blocks, blocks 1, 2, and 3. Block 1 is 8 kb and encompasses the 3' end to intron 9 of PHF19; block 2 extends from TRAF1 through 24 kb of intergenic sequence to exon 32 of C5; while block 3 (178 kb) contains the remainder of the C5 gene and CEP110 (Figure 1A). The LD structure in the Dutch population was similar to the structure reported by the International HapMap Project (unpublished data).
###end p 60
###begin title 61
###xml 50 58 50 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1/C5</italic>
###xml 90 98 <span type="species:ncbi:9606">Patients</span>
LD Structure and Haplotype Association across the TRAF1/C5 Region in Sample Set 1 (290 RA Patients and 254 Controls)
###end title 61
###begin p 62
###xml 153 158 153 158 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">(D'),</italic>
(A) Haplotype block structure was predicted on the basis of the strength of pairwise LD, which is presented as a 2x2 matrix; red represents very high LD (D'), white indicates absence of correlation between SNPs, and blue indicates high correlation with a low level of significance. SNPs that were chosen for haplotype analysis are indicated along the top by an asterisk.
###end p 62
###begin p 63
###xml 145 146 145 146 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 146 147 146 147 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 147 148 147 148 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 156 159 156 157 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#165;</sup>
###xml 244 245 242 243 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 316 317 314 315 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 382 390 <span type="species:ncbi:9606">patients</span>
(B) Using htSNPs from each block, indicated by the asterisk in (A), haplotypes were inferred with a certainty of above 98% as represented by the R2h value. yenComparisons were made between one haplotype versus all others in cases and controls. aThe protective haplotype that is significantly less frequent in cases. bThe susceptible haplotype that is significantly more frequent in patients.
###end p 63
###begin p 64
###xml 218 220 218 220 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 220 221 220 221 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 265 266 265 266 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
(C) Sliding window of the susceptible haplotype using consecutive two-SNP combinations of the htSNPs reveals that SNP14 and SNP15 account for most of the association observed. For each of the SNP pairs we show the -log10p-value. The dotted line indicates a nominal p-value of 0.005.
###end p 64
###begin p 65
###xml 290 291 290 291 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 291 292 291 292 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 292 293 292 293 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 347 348 347 348 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">R</italic>
###xml 348 349 348 349 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 349 350 349 350 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">h</sub>
###xml 554 562 554 562 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040278-g001">Figure 1</xref>
###xml 596 597 596 597 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 620 621 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 673 678 673 678 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 700 702 700 702 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 874 875 874 875 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">b</sup>
###xml 875 876 875 876 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 945 946 945 946 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">a</sup>
###xml 946 947 946 947 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1089 1090 1089 1090 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1102 1110 1102 1110 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040278-g001">Figure 1</xref>
###xml 1231 1236 1231 1236 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 1243 1250 1243 1250 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040278-t001">Table 1</xref>
###xml 1315 1316 1315 1316 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1316 1317 1316 1317 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1414 1419 1414 1419 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 1490 1491 1490 1491 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 1491 1492 1491 1492 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 1502 1510 1502 1510 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040278-g002">Figure 2</xref>
###xml 843 851 <span type="species:ncbi:9606">patients</span>
To further minimize haplotypic uncertainty and to identify the minimal combination of SNPs that provide maximum information content within each block, we scanned these two blocks independently using the software TagSNPs. In block 2 we identified a minimal set of eight htSNPs with a global R2h of 0.996, and in block 3 we found ten htSNPs with an R2h of 0.985, indicating that haplotypes can be inferred with >95% certainty. Haplotypes were predicted, and analyses from all blocks revealed that the association with RA was restricted to SNPs in block 2 (Figure 1B), as demonstrated by the global p-value of association (p < 0.05) and suggesting the possible involvement of TRAF1 and/or the 3' end of C5. Of the four common haplotypes capturing > 95% of the variation, two significantly associated haplotypes were observed, one increased in RA patients (susceptible haplotypebp = 0.039), and one over-represented in controls (protective haplotypeap = 0.012). By applying a two-marker sliding window analysis, we observed a significant peak centered on SNP14/rs10818488 and SNP15/rs2416808 (p = 0.0039) (Figure 1C). Using three- and five-marker windows did not alter the outcome, suggesting that the significance seen with the other TRAF1 SNPs (Table 1) may be due to LD. To explore this possibility, we analyzed the r2-values with respect to SNP14. We confirmed that the most significant SNPs, which are located in TRAF1 and the adjacent intergenic region, are highly correlated with SNP14 (r2 > 0.90) (Figure 2).
###end p 65
###begin title 66
RA-Associated SNPs are Highly Linked to SNP14
###end title 66
###begin p 67
###xml 13 14 13 14 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 14 15 14 15 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 159 161 159 161 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">10</sub>
###xml 178 179 178 179 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 252 253 252 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 283 284 283 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 284 285 284 285 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 389 390 389 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 402 404 402 404 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 194 202 <span type="species:ncbi:9606">patients</span>
Pairwise LD (r2) between associated SNP14/rs10818488 and all other SNPs genotyped was calculated. For each of the SNPs listed along the x-axis we show the -log10 (y-axis) of the p-values for RA patients versus controls. Dotted lines indicate a nominal p-value of 0.005 and a maximal r2 value of 1. In a logistics regression model, only SNP14/rs10818488 remained statistically significant (p = 6.16 x 10-4)
###end p 67
###begin title 68
Replication in Three Independent Sample Sets from The Netherlands, Sweden, and the US
###end title 68
###begin p 69
###xml 41 42 41 42 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 257 258 257 258 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 597 598 597 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 610 612 610 612 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 652 653 652 653 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 665 667 665 667 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 670 677 670 677 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040278-t002">Table 2</xref>
###xml 820 827 820 827 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040278-t002">Table 2</xref>
###xml 948 956 948 956 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="supplementary-material" rid="pmed-0040278-st003">Table S3</xref>
###xml 1148 1149 1148 1149 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1211 1212 1211 1212 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1224 1226 1224 1226 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;3</sup>
Six tagging SNPs which were significant (p < 0.05) in the initial study were selected for replication in a fully independent set of Dutch cases and controls (sample set 2). Of these, only SNP14/rs10818488 and SNP15/rs2416808 were statistically significant (p < 0.05). Haplotype and a two-marker sliding window analysis localized the strongest region of association to SNP14 and SNP15, confirming the results from sample set 1 (unpublished data). Combined analyses of the data from sample sets 1 and 2 showed an even stronger association for SNP14 (OR 1.34, 95% confidence interval [CI] 1.13-1.58; p = 5.56 x 10-4) and SNP15 (OR 1.33, 95% CI 1.13-1.57; p = 6.65 x 10-4) (Table 2). Although the other four SNPs did not reach statistical significance in sample set 2, they were highly significant in the combined analysis (Table 2). To evaluate putative modes of inheritance, we calculated genotype-specific ORs in the combined dataset as detailed in Table S3. All SNPs were consistent with an additive model. On the basis of forward conditional logistics regression, SNP14 remained in the model with a heterozygote (AG) OR of 1.38 (95% CI 1.04-1.83, p = 0.027) and a homozygote (AA) OR of 2.06 (95% CI 1.42-2.98, p = 1.29 x 10-3).
###end p 69
###begin p 70
Association of Significant SNPs in Four Independent Sample Sets
###end p 70
###begin p 71
###xml 139 140 139 140 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 152 159 152 159 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040278-t002">Table 2</xref>
###xml 423 424 423 424 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 436 438 436 438 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 488 489 488 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 501 503 501 503 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;5</sup>
###xml 506 513 506 513 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040278-t002">Table 2</xref>
###xml 711 712 711 712 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">r</italic>
###xml 712 713 712 713 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">2</sup>
###xml 853 854 853 854 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 865 872 865 872 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="table" rid="pmed-0040278-t002">Table 2</xref>
###xml 932 933 932 933 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 933 947 933 947 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">cases/controls</sub>
###xml 1006 1012 1006 1012 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">common</sub>
###xml 1037 1038 1037 1038 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 1038 1046 1038 1046 <sub xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">combined</sub>
###xml 1058 1060 1058 1060 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;8</sup>
###xml 57 65 <span type="species:ncbi:9606">patients</span>
###xml 185 193 <span type="species:ncbi:9606">patients</span>
###xml 260 268 <span type="species:ncbi:9606">patients</span>
Similar replication of three SNPs in a cohort of Swedish patients and controls (sample set 3) confirmed association with SNP14/rs10818488 (p = 0.0078) (Table 2). A combined analysis of patients and controls of European origin (Dutch and Swedish) with 2,244 RA patients and 1,524 controls (sample sets 1, 2, and 3) showed that the most significant associations could again be attributed to SNP14 (OR 1.24, 95% CI 1.11-1.38, p = 1.73 x 10-5) and SNP15/rs2416808 (OR 1.23, 95% CI 1.09-1.40, p = 7.21 x 10-5) (Table 2). Additionally, these findings were further replicated in a case-control sample set from the US. Since LD analysis in the original three sample sets showed SNP14 and SNP15 to be highly correlated (r2 > 0.98) we genotyped only SNP14 and confirmed that the minor susceptibility allele was associated with RA risk (OR 1.36, 95% CI 1.13-1.64; p = 0.001) (Table 2). Combined analysis of SNP14 in all four independent sets (ncases/controls = 2,719/1,999) yielded a highly significant association ORcommon=1.26, 95% CI 1.15-1.37, pcombined = 1.40 x 10-8) and a PAR of 6.1% (95% CI 4.0-8.5).
###end p 71
###begin title 72
Association with Autoantibody-Positive Disease
###end title 72
###begin p 73
###xml 353 355 353 355 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b027">27</xref>
###xml 385 390 385 390 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 391 393 391 393 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 560 561 560 561 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">n</italic>
###xml 709 710 709 710 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 722 724 722 724 <sup xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">&#8722;4</sup>
###xml 727 735 727 735 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040278-g003">Figure 3</xref>
###xml 971 972 971 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 108 116 <span type="species:ncbi:9606">patients</span>
###xml 467 475 <span type="species:ncbi:9606">patients</span>
###xml 1111 1119 <span type="species:ncbi:9606">patients</span>
RA is a heterogeneous disease with a considerable variation in phenotype as evidenced by the fact that some patients are autoantibody-positive whereas others are not. Antibodies to citrullinated protein antigens, called ACPAs, have gained much interest as current data suggest that ACPA-positive and negative RA may have different genetic risk factors [27]. To investigate whether the TRAF1/C5 region is associated with a specific phenotype of RA, we next stratified patients for autoantibody status from whom baseline ACPA and RF measurements were available (n = 1,814) Interestingly, SNP14/rs10818488 mainly predisposes to autoantibody-positive disease when compared to controls (OR 1.25, 95% CI 1.11-1.40, p = 2.27 x 10-4) (Figure 3A). Although we also observed an increase in the frequency of the A allele in autoantibody-positive as compared to autoantibody-negative disease, this difference did not reach formal statistical significance (OR 1.15, 95% CI 0.98-1.34, p = 0.0789). These data therefore suggest that the current genetic risk factor may be predominant in the autoantibody-positive subset of RA patients.
###end p 73
###begin title 74
The A Allele of SNP14 Is Associated with Distinct Phenotypes of RA
###end title 74
###begin p 75
###xml 147 148 147 148 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 46 54 <span type="species:ncbi:9606">patients</span>
###xml 296 304 <span type="species:ncbi:9606">patients</span>
(Top, table) The frequency of the A allele of patients from whom baseline autoantibody status (ACPA and RF) were available was calculated. ORs and p-values were calculated between each subgroup and controls, and indicated a predominantly higher frequency of the A allele in ACPA- and RF-positive patients.
###end p 75
###begin p 76
###xml 195 200 <span type="species:ncbi:12440">non-A</span>
(Bottom, bar graph) Progression of joint damage in Sharp-van der Heijde units ("Sharp score") is higher in the presence of the minor A allele of SNP14. Radiological data of 193 A carriers and 85 non-A carriers were available, and differences between the groups were calculated based on disease severity after 2 y corrected for baseline.
###end p 76
###begin title 77
Association with Severity
###end title 77
###begin p 78
###xml 166 174 166 174 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1/C5</italic>
###xml 541 549 541 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="fig" rid="pmed-0040278-g003">Figure 3</xref>
###xml 626 627 620 621 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">p</italic>
###xml 256 264 <span type="species:ncbi:9606">patients</span>
###xml 525 530 <span type="species:ncbi:12440">non-A</span>
###xml 584 589 <span type="species:ncbi:12440">non-A</span>
Because the clinical course of RA can vary considerably ranging from nonerosive disease to rapidly progressive joint damage, we also analyzed whether the SNPs in the TRAF1/C5 region were involved with RA progression. Annual X-rays of the hands and feet of patients were assigned Sharp-van der Heijde units, a combined score for bone erosions and joint space narrowing. Carriers of the minor susceptibility allele of SNP14/rs10818488 had an almost 2-fold higher severe disease course at 2 y after inclusion as compared to the non-A carriers (Figure 3B; mean +/- SE score of A carriers/non-A carriers, 11.4 +/- 1.4/7.1 +/- 1.8; p = 0.008) indicating that the A allele predisposes not only to RA susceptibility, but also to severity.
###end p 78
###begin title 79
SNP14/rs10818488 Is Located in a TFBS
###end title 79
###begin p 80
###xml 124 126 124 126 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b026">26</xref>
###xml 583 588 583 588 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 596 598 596 598 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
To investigate the potential functional effect of this SNP, we scanned for transcription factor binding sites using MAPPER [26]. The SNP14 susceptibility A allele encodes a potential binding site for EP300, a histone acetyl transferase that regulates transcription via chromatin remodeling. In the absence of this allele, the binding of EP300 to this region is predicted to be disrupted, potentially disturbing the epigenetic tag for transcriptional activation. We hypothesize that this putative transcription factor binding site may be involved in the regulation of the neighboring TRAF1 and/or C5 gene.
###end p 80
###begin title 81
Discussion
###end title 81
###begin p 82
###xml 51 56 51 56 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 57 59 57 59 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 444 452 444 452 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1/C5</italic>
###xml 616 618 616 618 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b028">28</xref>
Using a candidate-gene approach, we identified the TRAF1/C5 region on Chromosome 9q33-34 as a susceptibility and severity factor for RA. This region was also associated with RA in a large-scale genetic association study (Schrodi et al., unpublished data). It is, therefore, intriguing to see that these independent studies, in which the process leading to results differed, give similar results, and in doing so provide strong evidence for the TRAF1/C5 region as a true RA-associated genetic variant. The recent genome-wide study performed by the Wellcome Trust failed to identify this region as a candidate for RA [28]. Although it is difficult to speculate why this region was not detected in the Wellcome Trust Case Control Consortium study, we do note that none of the SNPs showing strong association in our hands was genotyped by the Wellcome Trust. Additionally, in line with our finding that this genetic risk factor is predominant in the autoantibody-positive subgroup, substratifications of the specific RA phenotypes may be needed to detect significant association.
###end p 82
###begin p 83
###xml 23 28 23 28 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 254 256 250 252 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b029">29</xref>
###xml 311 316 303 308 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 390 392 382 384 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b030">30</xref>
###xml 493 495 485 487 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b031">31</xref>
###xml 783 784 775 776 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b009">9</xref>
###xml 823 825 815 817 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 863 865 855 857 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 982 983 974 975 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b007">7</xref>
###xml 984 986 976 978 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b011">11</xref>
###xml 1165 1168 1157 1160 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5,</italic>
###xml 773 781 <span type="species:ncbi:9606">patients</span>
###xml 806 810 <span type="species:ncbi:10090">mice</span>
The protein encoded by TRAF1 is a member of the TNF receptor-associated factor (TRAF) protein family, which associates with and mediates the signal transduction from various receptors of the TNF receptor superfamily, including the receptor for TNFalpha [29]. In addition to a direct role in TNFalpha signaling, TRAF1 has also been implicated in the activation and proliferation of T cells [30] and is expressed ubiquitously by other cells of the immune system including monocytes and B cells [31]. It is therefore possible that TRAF1 could play a role in RA by aiding the maintenance of the proinflammatory environment. Likewise, studies have also shown that perpetuation of inflammation coincides with increased levels of the anaphylatoxin C5a in the synovial fluid of RA patients [9]. Further studies in mice identifying C5 as a candidate gene and showing that C5 deficiency results in lower incidence and less-severe disease course support the role of this gene in inflammation [7,11]. It is therefore likely that although the primary function of the complement system is to protect the host from microorganisms, a deregulated activity of its central component, C5, can play a substantial role in inflammatory diseases as well.
###end p 83
###begin p 84
###xml 335 340 323 328 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 345 347 333 335 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
In order to capture the variation within these candidate genes and potential regulatory regions, we genotyped both SNPs that were intragenic and those located 5' and 3' of the genes. Interestingly, the strongest replicated association was observed with SNP14/rs10818488, which maps to an intergenic region approximately10 kb from both TRAF1 and C5 and is present in a TFBS, which may regulate the transcriptional activity of its neighboring genes. However, formal testing of all known variation within this locus, both genetic and biological, will be necessary to pinpoint the precise biological process that is altered by the RA-associated variant(s) present in this region.
###end p 84
###begin p 85
###xml 276 281 276 281 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
###xml 282 284 282 284 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 750 752 750 752 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b032">32</xref>
###xml 359 367 <span type="species:ncbi:9606">patients</span>
We found a strong association of this region in all four independent sample sets which represent varying disease durations (<3 to >10 y) as well as a correlation with disease progression. More importantly, these phenotypic data on joint destruction not only indicate that the TRAF1/C5 region predisposes to RA, but also suggest that within the RA population, patients harboring the minor susceptibility allele of SNP14/rs10818488 tend to experience a more severe disease course. Although the above findings most likely exclude the possibility of a spurious association, especially since each case group was assigned an ethnically and geographically matched control group, background levels of population stratification as described by Cardon et al. [32] may exist in the different populations under study. It is therefore conceivable that the slight variation in the observed effect between the four populations may partially be due to varying sample sizes and background levels of population admixture.
###end p 85
###begin p 86
###xml 173 175 173 175 <xref xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" ref-type="bibr" rid="pmed-0040278-b033">33</xref>
###xml 621 629 <span type="species:ncbi:9606">patients</span>
RA is a common complex disease that results from the interaction of multiple genetic variants, each with relatively low penetrance, with an array of environmental triggers [33]. In advance of a genetic profile that can accurately pinpoint individuals at risk, identification of these genetic variants can provide insight into the underlying mechanisms of disease and the specific pathways associated with disease induction and/or progression. Understanding the function of these common disease-associated variants will be important to identify potential targets for intervention strategies that could prove useful to all patients, whether or not they carry the disease-associated variant.
###end p 86
###begin p 87
###xml 182 190 182 190 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1/C5</italic>
In summary, this study provides robust evidence from four independent sample sets (two of Dutch origin, one of Swedish descent, and one from the US) that genetic variants within the TRAF1/C5 region are associated with RA, indicating a possible role for these immune-related genes in the biological process underlying RA disease pathogenesis.
###end p 87
###begin title 88
Limitations of This Study
###end title 88
###begin p 89
###xml 22 30 22 30 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1/C5</italic>
###xml 628 636 628 636 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1/C5</italic>
###xml 787 795 787 795 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1/C5</italic>
###xml 72 77 <span type="species:ncbi:9606">human</span>
Our study defines the TRAF1/C5 as a novel genetic region present in the human genome that predisposes to RA. However, the causative variation (SNP) or the biological mechanism explaining this association is not yet known. Although it could be that the current identified polymorphism is causative, other proxies in high LD with this SNP could also be responsible for the observed association, an issue that can be addressed in more detailed by functional studies. Furthermore, although our data indicate a predominant association with autoantibody-positive disease, our study is underpowered to exclude the possibility that the TRAF1/C5 region also predisposes to autoantibody-negative disease. By combining information obtained from other cohorts in which both the autoantibody and the TRAF1/C5 status are known, this question should be resolved in the future. As it has been indicated that distinct genetic risk factors underlie either autoantibody-positive or autoantibody-negative disease, such additional information would provide more detailed knowledge on the genetic heterogeneity of these two distinct phenotypes of RA.
###end p 89
###begin title 90
Supporting Information
###end title 90
###begin title 91
Genotyping Methods
###end title 91
###begin p 92
(26 KB DOC)
###end p 92
###begin p 93
Click here for additional data file.
###end p 93
###begin title 94
###xml 31 39 <span type="species:ncbi:9606">Patients</span>
Clinical Characteristics of RA Patients from Four Independent Sample Sets
###end title 94
###begin p 95
(21 KB XLS)
###end p 95
###begin p 96
Click here for additional data file.
###end p 96
###begin title 97
Mantel-Haenzel OR and P for Combined Sets
###end title 97
###begin p 98
(22 KB XLS)
###end p 98
###begin p 99
Click here for additional data file.
###end p 99
###begin title 100
Genotypic Odds Ratios for the Most Significant SNPs in Sample Sets 1 and 2
###end title 100
###begin p 101
(21 KB XLS)
###end p 101
###begin p 102
Click here for additional data file.
###end p 102
###begin title 103
Primers and Conditions for PCR_RFLP
###end title 103
###begin p 104
(21 KB XLS)
###end p 104
###begin p 105
Click here for additional data file.
###end p 105
###begin title 106
Accession Numbers
###end title 106
###begin p 107
###xml 77 79 77 79 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">C5</italic>
###xml 93 99 93 99 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">CEP110</italic>
###xml 113 118 113 118 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">PHF19</italic>
###xml 132 137 132 137 <italic xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">TRAF1</italic>
The GenBank () accession numbers for the genes discussed in this article are C5 (NM_001735); CEP110 (NM_007018); PHF19 (XM_045308); TRAF1 (NM_005658). The ExPASy UniProtKB/Swiss-Prot () accession number for EP300 is Q09472.
###end p 107
###begin p 108
We would like to thank A. Bakker, J. Schonkeren, and S. Vrijmoet for their support as well as D. Kremer and Prof. E. Slagboom for their expert assistance with the Sequenom genotyping platform.
###end p 108
###begin title 109
Abbreviations
###end title 109
###begin p 110
anti-citrullinated protein antibody
###end p 110
###begin p 111
confidence interval
###end p 111
###begin p 112
###xml 0 5 <span type="species:ncbi:9606">human</span>
human leucocyte antigen
###end p 112
###begin p 113
haplotype tagging SNP
###end p 113
###begin p 114
linkage disequilibrium
###end p 114
###begin p 115
odds ratio
###end p 115
###begin p 116
rheumatoid arthritis
###end p 116
###begin p 117
rheumatoid factor
###end p 117
###begin p 118
single-nucleotide polymorphism
###end p 118
###begin p 119
tumor necrosis factor
###end p 119
###begin title 120
References
###end title 120
###begin article-title 121
Evolving concepts of rheumatoid arthritis
###end article-title 121
###begin article-title 122
The genetics revolution and the assault on rheumatoid arthritis
###end article-title 122
###begin article-title 123
Characterizing the quantitative genetic contribution to rheumatoid arthritis using data from twins
###end article-title 123
###begin article-title 124
The contribution of HLA to rheumatoid arthritis
###end article-title 124
###begin article-title 125
A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis
###end article-title 125
###begin article-title 126
Current and new antitumor necrosis factor agents in perspective
###end article-title 126
###begin article-title 127
###xml 76 80 <span type="species:ncbi:10090">mice</span>
A role for complement in antibody-mediated inflammation: C5-deficient DBA/1 mice are resistant to collagen-induced arthritis
###end article-title 127
###begin article-title 128
Anti-C5 monoclonal antibody therapy prevents collagen-induced arthritis and ameliorates established disease
###end article-title 128
###begin article-title 129
Terminal complement pathway activation and low lysis inhibitors in rheumatoid arthritis synovial fluid
###end article-title 129
###begin article-title 130
Essential role for the C5a receptor in regulating the effector phase of synovial infiltration and joint destruction in experimental arthritis
###end article-title 130
###begin article-title 131
Genetic influences on the end-stage effector phase of arthritis
###end article-title 131
###begin article-title 132
Investigation of susceptibility loci identified in the UK rheumatoid arthritis whole-genome scan in a further series of 217 UK affected sibling pairs
###end article-title 132
###begin article-title 133
The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis
###end article-title 133
###begin article-title 134
Tumour necrosis factor alpha gene polymorphisms in rheumatoid arthritis: association with susceptibility to, or severity of, disease?
###end article-title 134
###begin article-title 135
###xml 77 85 <span type="species:ncbi:9606">patients</span>
Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): A randomized, controlled trial
###end article-title 135
###begin article-title 136
The Leiden Early Arthritis Clinic
###end article-title 136
###begin article-title 137
A gene-environment interaction between smoking and shared epitope genes in HLA-DR provides a high risk of seropositive rheumatoid arthritis
###end article-title 137
###begin article-title 138
Haploview: Analysis and visualization of LD and haplotype maps
###end article-title 138
###begin article-title 139
###xml 41 46 <span type="species:ncbi:9606">human</span>
The structure of haplotype blocks in the human genome
###end article-title 139
###begin article-title 140
Choosing haplotype-tagging SNPS based on unphased genotype data using a preliminary sample of unrelated subjects with an example from the Multiethnic Cohort Study
###end article-title 140
###begin article-title 141
Score tests for association between traits and haplotypes when linkage phase is ambiguous
###end article-title 141
###begin article-title 142
EasyMA: A program for the meta-analysis of clinical trials
###end article-title 142
###begin article-title 143
Meta-analysis of genetic association studies supports a contribution of common variants to susceptibility to common disease
###end article-title 143
###begin article-title 144
Statistical methods in cancer research. Volume I-The analysis of case-control studies
###end article-title 144
###begin article-title 145
Plain X-rays in rheumatoid arthritis: Overview of scoring methods, their reliability and applicability
###end article-title 145
###begin article-title 146
MAPPER: A search engine for the computational identification of putative transcription factor binding sites in multiple genomes
###end article-title 146
###begin article-title 147
The devil in the details: The emerging role of anticitrulline autoimmunity in rheumatoid arthritis
###end article-title 147
###begin article-title 148
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls
###end article-title 148
###begin article-title 149
The TNF-receptor-associated factor family: Scaffold molecules for cytokine receptors, kinases and their regulators
###end article-title 149
###begin article-title 150
A critical role for TNF receptor-associated factor 1 and Bim down-regulation in CD8 memory T cell survival
###end article-title 150
###begin article-title 151
TNFR-associated factor family protein expression in normal tissues and lymphoid malignancies
###end article-title 151
###begin article-title 152
Population stratification and spurious allelic association
###end article-title 152
###begin article-title 153
Gene-gene and gene-environment interactions involving HLA-DRB1, PTPN22, and smoking in two subsets of rheumatoid arthritis
###end article-title 153
###begin p 154
###xml 0 21 0 21 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Author contributions.</bold>
###xml 158 161 <span type="species:ncbi:31658">CFA</span>
###xml 204 212 <span type="species:ncbi:9606">patients</span>
###xml 229 232 <span type="species:ncbi:31658">CFA</span>
###xml 334 337 <span type="species:ncbi:31658">CFA</span>
###xml 444 452 <span type="species:ncbi:9606">patients</span>
###xml 467 470 <span type="species:ncbi:31658">CFA</span>
###xml 612 620 <span type="species:ncbi:9606">patients</span>
###xml 936 944 <span type="species:ncbi:9606">patients</span>
Author contributions. FASK, LP, SJS, LA, LK, TWJH, and REMT designed the study. FASK, LP, SJS, GSR, AHM, JHD, ABB, LK, TWJH, and REMT analyzed the data. AHM, CFA, WV, LA, ABB, LK, TWJH, and REMT enrolled patients. FASK, LP, RBM, CFA, WV, JHD, LA, ABB, LK, TWJH, and REMT contributed to writing the paper. FASK, LP, RBM, SJS, MS, GSR, CFA, LA, ABB, LK, TWJH, and REMT collected data or performed experiments for this study. MS genotyped Swedish patients and controls. CFA provided data and material of one of the cohorts investigated in this paper, being the principal investigator of the study that included the patients in this cohort, and assisted with the interpretation of clinical data. LA was principal investigator (together with LK) of EIRA, the largest of the studies that was used for replication. LA was responsible for the design of EIRA and also for the organization of data collection. LK contributed to the collection of patients and controls in the Swedish EIRA study.
###end p 154
###begin p 155
###xml 0 8 0 8 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Funding:</bold>
Funding: This work was supported by funds from the Dutch Arthritis Foundation, The Netherlands Organisation for Scientific Research and the European Community's FP6 funding Project 018661 Autocure. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
###end p 155
###begin p 156
###xml 0 20 0 20 <bold xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML">Competing Interests:</bold>
Competing Interests: Drs. Begovich and Schrodi own stock options in Applied Biosystems and Celera Genomics. The remaining authors have declared no conflicts of interest.
###end p 156

